Member Info for WeTookPelham

Yes a great summary, for both newcomers and as a reminder to those who've been here a while. Thank you for that VanVan, much appreciated.
As with all AIM shares there are risks of course as VanVan mentioned, but VanVans post reminds us of the (potentially huge?) upside to Scancell.

I'm sure we've already has this posted about Gilead's use of Ichors Trigrid delivery system?
https://www.pubfacts.com/detail/30235286/Safety-and-tolerability-of-HIV-1-multiantigen-pDNA-vaccine-given-with-IL-12-plasmid-DNA-via-electrop

But is anyone the wiser about Trigrid 2.0, the IND etc etc. Has anyone tried contacting Ichor? I emailed them about a week ago but no response yet.
Strangely when you do a search for "ichor trigrid 2.0" you seem to only get back results relating to Scancells involvement.

...presenting Trigrid at World Vaccine & Immunotherapy 2018

https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/agenda-day-2.stm#a4cD0000000fyBs

Just a thought and something to discuss. As we "still" await some significant, and hopefully SP altering (in an upwards trajectory) news, I think the BOD may be aware of the PI's chatter about the generous increases in salaries/remuneration/consulting fees etc they have been awarding themselves.

Although they can brush off questions, I'm sure they would like to avoid these awkward questions at the AGM about this, so in some (very small) way it's their benefit that we do get some news between now and the AGM...IMO.

I appreciate that obviously news can only come when it's ready. But who know's, as several have mentioned, the silence has been deafening for a good long while now, Monday could be the day that changes everything. With so much going on in the background, it seems inconceivable that some ground shaking news isn't around the corner.

P.s. Likewise I'll be topping up on Monday...if it's still around this price :)

https://www.calculuscapital.com/2018-nobel-prize-in-medicine-awarded-to-cancer-immuno-oncology-researchers/

"...This is a seminal day for those working in the field of immuno-oncology, including those at Calculus’ portfolio companies Oxford BioTherapeutics (OBT) and Scancell, as it is the first time that the development of cancer therapy has been recognised with a Nobel Prize."

"...Similarly, Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. The first vaccine, SCIB1, is being developed for the treatment of late stage melanoma, with the second, SCIB2, for the treatment of solid tumours, initially targeting non-small cell lung cancer."

Do you have a link crumbs?
They always have included Scancell right?
Maybe impending news so no coverage???

So it looks like November is still the case? Like you say Konar, it appears that they announce the winners in November and award the prize in January, if that page you posted reads as I think it does:

https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/round-2-shortlisted-teams

"Why Scancell is combining SCIB1 and SCIB2 with checkpoint inhibitors #cancervaccines"
https://twitter.com/scancellpharma/status/1047047522978553856?s=20

SCANCELL Retweeted
Michael Gilman
"Michael Gilman
@michael_gilman
Today’s #NobelPrize is a nearly perfect example of how a basic science discovery - a true a-ha moment"
https://twitter.com/michael_gilman/status/1046713980713160704?s=20

..2018...later today:

https://www.parkerici.org/2018/09/25/parker-institute-researchers-featured-at-fourth-international-immunotherapy-conference-2018-in-new-york-cicon18/

"CANCER VACCINES: NOVEL VACCINE PLATFORMS AND COMBINATIONS
Oct. 2, 2018, 8:15 a.m.-12:45 p.m. EDT

Nina Bhardwaj, M.D., Ph.D., a Parker Institute investigator at the Icahn School of Medicine at Mount Sinai chairs this session on cancer vaccines. Speakers include Parker Institute scientists Catherine Wu, M.D., of the Dana-Farber Cancer Institute and Robert Schreiber, Ph.D., of Washington University. Other speakers include Ugur Sahin, Ph.D., of BioNTech."

Professor Ugur Sahin who is MD of TRON and Co-Founder and CEO of BioNTech and more importantly for Scancell holders, is part of the CRUK Grand Challenge team:
https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/shortlistedteamdurrant

Scancell seem to have footprints all over the conference? And because of those in involved in the Grand Challenge it seems Scancell have "insiders" in all the big and relevant immunotherapy circles?

Incidentally that first excerpt was taken form the Parker Institutes website as they I assume are leading that talk? I've always wondered if the Parker Institute is the "leftfield"? They certainly have the money. And I don't think CRUK would mind if their toes got stepped on a little?

Having a problem with pasting links it seems, so re-posting:
http://www.scancell.co.uk/news/regulatory-news/scancell-to-conduct-phase-ii-checkpoint-inhibitor-combination-study-with-scib1-with-leading-us-melanoma-specialists

P.S. if you do a web search for "Jennifer Wargo Allison" you can clearly make out they work closely together, probably stating the obvious but worth pointing out...perhaps.

MD Anderson and Scancell:
http://www.scancell.co.uk/news/regulatory-news/scancell-to-conduct-phase-ii-checkpoint-inhibitor-combination-study-with-scib1-with-leading-us-melanoma-specialists

..."Harvard, MD Anderson, Memorial Sloan Kettering, University of Colorado clinical team to lead checkpoint inhibitor combination trial with SCIB1 "

"...Joining Dr Flaherty are Dr Jennifer Wargo of the Department of Surgical Oncology at MD Anderson, Dr Michael Davies of the Department of Melanoma Oncology at MD Anderson"

James P Allison (A.K.A. Jim Allison), Ph.D, is chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center:
https://www.mdanderson.org/newsroom/2018/10/md-anderson-immunologist-jim-allison-awarded-nobel-prize.html?cmpid=newsroom_immunotherapy_nobel_twitter

So I assume we can safely say there is a connection with Scancell and JP Allison?

All the Scancell presentations links from scrumpys tweets, when it asks you to login, just skip that bit:

https://event.crowdcompass.com/cancerimmunotherapy/activity/yWoKBethDj

https://event.crowdcompass.com/cancerimmunotherapy/activity/k59zMDe04R

https://event.crowdcompass.com/cancerimmunotherapy/activity/JQL7OPZGlY

Lots of big names at the conference too.

All the tweets/retweets are on Scancells Twitter page, apologies, I didn't realise this earlier:
https://mobile.twitter.com/scancellpharma

Another tweet ( via goosed on advfn again) this time direct from Scancell... Significant perhaps?

22:27 gooosed: Https://twitter.com/scancellpharma/status/1046508845336391680

"....introducing a new #moditope cancer target...homocitrulline"

Courtesy of goosed on ADVFN/scumpy on Twitter - Now why didn't they RNS about this lol?

Https://twitter.com/Scrumpy222/status/1046453099097976832

Https://twitter.com/Scrumpy222/status/1046453798292656129

Https://twitter.com/Scrumpy222/status/1046454190300704768

Thanks Ray and 2cv.
Last year this was the schedule.
https://www.investegate.co.uk/scancell-hlds--sclp-/rns/notice-of-agm/201709140700076869Q/

P.s. Over on advfn, they're making (valid IMO) points about big and perhaps unjustified pay increases for the board.

...The agm can be held? They need to give (at least?) four weeks notice via RNS too right? C7 I know you already mentioned this but struggling to find the post.

...but another example that big pharma happy to spend the big bucks on small bios...
Although must confess to never hearing of Alexion before, they clearly have clout.
https://www.businesswire.com/news/home/20180926005248/en/Alexion-Acquire-Syntimmune

Hi TF, whats the significance of the Scancell news appearing on Alliance News, are they a big deal?